Forendo Pharma is a drug discovery and development company with a core competence in tissue specific regulation of sex hormones. Forendo founders, Risto Lammintausta, Professors Matti Poutanen and Antti Perheentupa bring a unique mixture of scientific, development, and clinical expertise to develop first in class therapies for intracrine diseases. Forendo discovery and development efforts focus on 17-HSD1 inhibitors for the treatment of endometriosis and on earlier programs from its HSD platform for other hormone dependent diseases. The company is also developing Fispemifene, the first selective estrogen receptor modulator for the treatment of symptoms of low testosterone. Forendo is based in Turku, Finland.
Forendo Pharma today announced the completion of Phase 1 studies in healthy volunteers for its lead development program in endometriosis, FOR-6219, and provided a development outlook
2019/12/11Forendo Pharma today announces signing of a License and Collaboration Agreement with Novartis.
2019/07/19Forendo Pharma today announces that Sunstone Life Science Ventures has made a €5 million investment in Forendo
Forendo Commences Phase Ia Study for FOR-6219 for Endometriosis
Forendo Pharma, today announces it has received clinical trial authorisation (CTA) from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to commence a study for its lead program FOR-6219
Forendo Pharma today announces that it has been granted a €3 million R&D loan from Business Finland, for the development of a novel drug for endometriosis treatment. Business Finland is the most important public funding agency for research funding in Finland.
Forendo Pharma, a drug development company developing novel oral treatments for endometriosis patients, announces the nomination of its Scientific Advisory Board today. Forendo is developing tissue-specific hormone inhibitors to rebalance local estrogen metabolism in endometrial tissues. The key differentiator of the company’s lead HSD17B1 inhibitor compared to other drug treatments is the ability to act locally without impacting the systemic estrogen levels as demonstrated in preclinical models. This selective activity is expected to allow safer long-term treatment of this chronic disease without harmful symptoms of estrogen deficiency.
